Starting Dose for Vyvanse in an 8-Year-Old with Rebound Irritability from Adderall
Start Vyvanse at 30 mg once daily in the morning for this 8-year-old patient with a history of rebound irritability on Adderall XR. 1
Rationale for 30 mg Starting Dose
The FDA-approved starting dose for Vyvanse (lisdexamfetamine) in pediatric patients 6 years and older is 30 mg once daily in the morning 1. This is the standard recommended starting point regardless of prior stimulant exposure, as Vyvanse has distinct pharmacokinetic properties that make direct dose conversion from other stimulants unreliable.
Why 30 mg Rather Than 20 mg
- The 30 mg dose is the established therapeutic starting point that balances efficacy with tolerability in the pediatric ADHD population 1
- Vyvanse's prodrug formulation provides smoother, more sustained delivery of d-amphetamine throughout the day, which specifically addresses the rebound irritability problem this patient experienced with Adderall XR 2, 3
- Starting at 20 mg may be subtherapeutic and unnecessarily prolong the time to achieve symptom control, as the FDA label explicitly recommends 30 mg as the starting dose with weekly titration in 10-20 mg increments up to 70 mg maximum 1
Addressing the Rebound Irritability Issue
Vyvanse is particularly well-suited for patients with rebound irritability because its prodrug mechanism creates a more gradual onset and offset of therapeutic effects compared to Adderall XR 2, 3. The key differences include:
- Enzymatic conversion in red blood cells produces steady d-amphetamine levels rather than the biphasic release pattern of Adderall XR 2
- Extended duration of action up to 14 hours reduces the sharp decline in medication effect that triggers rebound symptoms 2
- Lower peak-to-trough fluctuations minimize the behavioral changes associated with medication wearing off 3
Management Strategy from Guidelines
The American Academy of Child and Adolescent Psychiatry specifically addresses behavioral rebound with stimulants, recommending strategies such as overlapping dosing patterns, switching to longer-acting formulations, or combining immediate-release with sustained-release products 4. Vyvanse represents the longest-acting single-dose stimulant option available, making it an ideal choice for this clinical scenario 2.
Titration Plan
After starting at 30 mg:
- Assess response after approximately one week at the initial dose 1
- Titrate in 10 mg or 20 mg increments at weekly intervals based on symptom control and tolerability 1
- Maximum dose is 70 mg once daily for pediatric patients 1
- Monitor specifically for evening irritability to confirm resolution of the rebound phenomenon 4
Important Monitoring Considerations
Watch for common adverse effects including decreased appetite, insomnia, upper abdominal pain, headache, and irritability (which should be distinguished from rebound irritability) 3. The irritability from Vyvanse itself typically occurs during peak effect rather than during wear-off 4.
Timing of Administration
- Give in the morning with or without food 1
- Avoid afternoon doses due to potential for insomnia 1
- The once-daily dosing eliminates the need for school administration, which is a practical advantage over shorter-acting formulations
Clinical Pitfalls to Avoid
Do not start at 20 mg simply because the patient is young or had issues with another stimulant. The 30 mg starting dose is evidence-based and appropriate for children as young as 6 years 1. Starting too low may lead to inadequate response and premature abandonment of an otherwise effective medication.
Do not assume equivalent dosing between Adderall and Vyvanse. While both are amphetamine-based, Vyvanse's prodrug formulation means that 30 mg of lisdexamfetamine does not equal 30 mg of mixed amphetamine salts 5, 2. The conversion is not linear, and clinical response should guide dosing rather than mathematical calculations.
Distinguish between peak-dose irritability and rebound irritability when assessing response 4. If irritability occurs in the morning or midday, it may represent excessive dosing or a peak effect. If it occurs in late afternoon or evening, it suggests either rebound from medication wearing off or insufficient coverage of ADHD symptoms during those hours.